X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Sun Pharma with MYLAN INC. - US - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUN PHARMA vs MYLAN (US) - Comparison Results

SUN PHARMA    Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 SUN PHARMA   MYLAN
EQUITY SHARE DATA
    SUN PHARMA
Mar-17
MYLAN
Dec-14
SUN PHARMA/
MYLAN
5-Yr Chart
Click to enlarge
High Rs8423,830-   
Low Rs5722,699-   
Sales per share (Unadj.) Rs131.61,311.3-  
Earnings per share (Unadj.) Rs32.7158.0-  
Cash flow per share (Unadj.) Rs38.0254.3-  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs152.7651.9-  
Shares outstanding (eoy) m2,399.26378.37-   
Bonus/Rights/Conversions -OI-  
Price / Sales ratio x5.42.5 215.8%   
Avg P/E ratio x21.620.7 104.6%  
P/CF ratio (eoy) x18.612.8 145.1%  
Price / Book Value ratio x4.65.0 92.5%  
Dividend payout %10.70-   
Avg Mkt Cap Rs m1,696,8771,235,346 137.4%   
No. of employees `00017.525.0 70.1%   
Total wages/salary Rs m49,0230-   
Avg. sales/employee Rs Th18,028.319,846.6 90.8%   
Avg. wages/employee Rs Th2,798.80-   
Avg. net profit/employee Rs Th4,479.52,390.8 187.4%   
INCOME DATA
Net Sales Rs m315,784496,164 63.6%  
Other income Rs m6,232-2,892 -215.5%   
Total revenues Rs m322,016493,272 65.3%   
Gross profit Rs m100,893123,398 81.8%  
Depreciation Rs m12,64836,441 34.7%   
Interest Rs m3,99821,402 18.7%   
Profit before tax Rs m90,47962,663 144.4%   
Minority Interest Rs m0-257 0.0%   
Prior Period Items Rs m990-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m12,1162,635 459.8%   
Profit after tax Rs m78,46259,771 131.3%  
Gross profit margin %31.924.9 128.5%  
Effective tax rate %13.44.2 318.4%   
Net profit margin %24.812.0 206.3%  
BALANCE SHEET DATA
Current assets Rs m329,537436,194 75.5%   
Current liabilities Rs m178,870341,017 52.5%   
Net working cap to sales %47.719.2 248.7%  
Current ratio x1.81.3 144.0%  
Inventory Days Days7978 101.2%  
Debtors Days Days83107 77.6%  
Net fixed assets Rs m204,766114,786 178.4%   
Share capital Rs m2,39917,546 13.7%   
"Free" reserves Rs m363,9970-   
Net worth Rs m366,397246,643 148.6%   
Long term debt Rs m14,361368,460 3.9%   
Total assets Rs m614,102993,454 61.8%  
Interest coverage x23.63.9 601.6%   
Debt to equity ratio x01.5 2.6%  
Sales to assets ratio x0.50.5 103.0%   
Return on assets %13.48.2 164.3%  
Return on equity %21.424.2 88.4%  
Return on capital %24.813.6 182.3%  
Exports to sales %00-   
Imports to sales %00-   
Net fx Rs m19,6340-   
CASH FLOW
From Operations Rs m70,82265,221 108.6%  
From Investments Rs m-42,216-51,435 82.1%  
From Financial Activity Rs m-22,854-17,186 133.0%  
Net Cashflow Rs m6,107-3,400 -179.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 64.27 Rs / USD

Compare SUN PHARMA With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare SUN PHARMA With: AJANTA PHARMA  STERLING BIOTECH  NOVARTIS  UNICHEM LAB  AUROBINDO PHARMA  



Today's Market

Weak Start to the Week; PSU & Metal Stocks Fall(Closing)

Indian share markets continued to witness selling pressure in the afternoon session as benchmark Sensex slipped below the 34,000-mark.

Related Views On News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUN PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK SUN PHARMA

  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUN PHARMA WITH

MARKET STATS